Literature DB >> 7535490

Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system?

N Barden1, J M Reul, F Holsboer.   

Abstract

Patients suffering from severe depression often show an increased activity of the hypothalamic-pituitary-adrenocortical (HPA) system, a premature escape from the cortisol suppressant action of dexamethasone, and a number of other neuroendocrine changes. This might be explained by defective glucocorticoid feedback inhibition. Normalization of the hyperactive HPA system occurs during successful antidepressant pharmacotherapy of depressive illness, and this could be achieved by antidepressant-induced increases in the cellular corticosteroid receptors, rendering the HPA system more susceptible to feedback inhibition by cortisol. Both mineralocorticoid- and glucocorticoid-receptor mRNA levels and hormone-binding activities are found to be increased following treatment of different cell lines or animals with antidepressants. Since the timecourse of antidepressant actions on corticosteroid receptors follows more closely that of clinical improvement of depression, antidepressants might elevate mood in depressives through their long-term effects on HPA regulation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7535490     DOI: 10.1016/0166-2236(95)93942-q

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  52 in total

1.  Plasma membrane calcium pump isoform 1 gene expression is repressed by corticosterone and stress in rat hippocampus.

Authors:  A Bhargava; O C Meijer; M F Dallman; D Pearce
Journal:  J Neurosci       Date:  2000-05-01       Impact factor: 6.167

2.  Lateralized effects of medial prefrontal cortex lesions on neuroendocrine and autonomic stress responses in rats.

Authors:  R M Sullivan; A Gratton
Journal:  J Neurosci       Date:  1999-04-01       Impact factor: 6.167

3.  Enhancement of serotonin uptake by cortisol: a possible link between stress and depression.

Authors:  G E Tafet; M Toister-Achituv; M Shinitzky
Journal:  Cogn Affect Behav Neurosci       Date:  2001-03       Impact factor: 3.282

4.  Neurodevelopmental liabilities of substance abuse.

Authors:  Tomas Palomo; Trevor Archer; Richard J Beninger; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2002-06       Impact factor: 3.911

Review 5.  [New developments in pharmacotherapy of depression].

Authors:  R Rupprecht; Th C Baghai; H-J Möller
Journal:  Nervenarzt       Date:  2003-05-10       Impact factor: 1.214

6.  The mineralocorticoid receptor agonist, fludrocortisone, differentially inhibits pituitary-adrenal activity in humans with psychotic major depression.

Authors:  Anna Lembke; Rowena Gomez; Lakshika Tenakoon; Jennifer Keller; Gregory Cohen; Gordon H Williams; Fredric B Kraemer; Alan F Schatzberg
Journal:  Psychoneuroendocrinology       Date:  2012-06-21       Impact factor: 4.905

7.  Time course of hypothalamic-pituitary-adrenocortical axis activity during treatment with reboxetine and mirtazapine in depressed patients.

Authors:  Cornelius Schüle; Thomas C Baghai; Daniela Eser; Peter Zwanzger; Martina Jordan; Renate Buechs; Rainer Rupprecht
Journal:  Psychopharmacology (Berl)       Date:  2006-04-22       Impact factor: 4.530

Review 8.  Neuroendocrine effects on mood.

Authors:  Margaret G Spinelli
Journal:  Rev Endocr Metab Disord       Date:  2005-05       Impact factor: 6.514

9.  Chronic mild stress induces behavioral and physiological changes, and may alter serotonin 1A receptor function, in male and cycling female rats.

Authors:  Angela J Grippo; Nicole R Sullivan; Katerina J Damjanoska; James W Crane; Gonzalo A Carrasco; Ju Shi; Zhuo Chen; Francisca Garcia; Nancy A Muma; Louis D Van de Kar
Journal:  Psychopharmacology (Berl)       Date:  2004-12-24       Impact factor: 4.530

Review 10.  [The significance of stress: its role in the auditory system and the pathogenesis of tinnitus].

Authors:  B Mazurek; T Stöver; H Haupt; B F Klapp; M Adli; J Gross; A J Szczepek
Journal:  HNO       Date:  2010-02       Impact factor: 1.284

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.